Gilead Sciences, Inc. (GILD) Presents at Wells Fargo twentieth Annual Healthcare Conference

Mohit Bansal
Senior Equity Analyst

Awesome. Thank you very much for joining us today. My name is Mohit Bansal. I’m one of the biopharma analysts, and I’m very happy to have fourth year in a row.

Andrew Dickinson
Chief Financial Officer

Thank you.

Mohit Bansal
Senior Equity Analyst

With us, Andy Dickinson, the CFO of Gilead. Thank you, Andy, for joining us today. And I’ll give the floor to you for opening remarks and exciting times ahead of Gilead.

Andrew Dickinson
Chief Financial Officer

No, thank you. Thanks for having us. It’s our pleasure to be here again. It’s a great conference. It is exciting times for Gilead. I think we — you saw we had an incredible second quarter, strong performance across all of our business units, increased our guidance for the year, both kind of on the top line, the bottom line, saw really strong growth in our HIV prevention business, among others, and obviously have launched what we think is a transformational therapy for HIV prevention and Yeztugo.

So it’s a great quarter for Gilead. It’s been a strong year for us and on the heels of a number of strong years. So it’s an exciting time in the company, and we’re really pleased with where we are.